Jump to content

Mesothelioma Misdiagnosis

From WikiMesothelioma — Mesothelioma Knowledge Base
Mesothelioma Misdiagnosis
How Often, Why, and What to Do
Pathology Error Rate (Developed) ~14% of mesothelioma diagnoses
Error Rate (Resource-Limited) Up to ~50%
Pleural Misdiagnosis (Initial) ~1 in 4 patients
Most Common Wrong Call Lung adenocarcinoma (pleural); ovarian cancer (peritoneal)
Time to Specialist Referral Median 6.5 months from symptom onset
Biopsy False-Negative (Cope Needle) 57.1%
Localized vs. Distant 5-Yr Survival ~20% vs. ~8%
Free Case Review →

Executive Summary

Mesothelioma misdiagnosis is one of the most consequential problems in rare-cancer medicine. Peer-reviewed expert-review studies consistently show that a large share of outside mesothelioma diagnoses are revised when examined by specialist thoracic pathologists: a Chinese two-center study by Guo et al. 2017 confirmed only 52 of 92 (56.5%) specimens submitted from reference hospitals, with the pleural confirmation rate dropping to just 12 of 34 (35.3%).[1][2] For pleural mesothelioma specifically, Monte Carlo analyses of cancer registry data suggest that 17–25% of registry-recorded cases were ultimately reclassified on expert review, and community-level misdiagnosis most commonly labels the tumor as lung cancer or adenocarcinoma — tumors whose morphology closely mimics epithelioid mesothelioma under the microscope.[3][4][5]

The delay between symptom onset and correct diagnosis is among the longest of any cancer. A retrospective study of 66 malignant pleural mesothelioma (MPM) patients by Gregório and colleagues documented a median of 6.5 months from first symptom to specialist visit, with an additional 1.5 months to histopathological confirmation and another 1.7 months to treatment initiation.[6] Expert pathology review studies routinely overturn or question a substantial share of mesothelioma diagnoses made at non-specialist centers: the French National Mesothelioma Surveillance Program confirmed only 67% of submitted cases, and a two-center Chinese study (Guo et al. 2017) confirmed mesothelioma in just 52 of 92 specimens (56.5%), dropping to 35.3% for pleural cases alone.[1][4]

These errors are not academic. Each month of diagnostic delay compresses the window for curative-intent surgery and shifts treatment from potentially life-extending pleurectomy/decortication or cytoreductive surgery toward palliative care. The five-year survival rate for localized pleural mesothelioma is approximately 20%, compared to roughly 8% for distant disease — a gap that diagnostic delay meaningfully widens by moving patients from stage I–II into stage III–IV before treatment can begin.[7][8] Patients who obtain a second opinion at a specialist mesothelioma center are substantially more likely to have their diagnosis revised, re-staged, and routed to treatment teams with the immunohistochemistry panels — calretinin, WT-1, D2-40, claudin-4, BAP1, and MTAP — required to distinguish mesothelioma from its imitators.[9][5][10]

At-a-Glance

Mesothelioma misdiagnosis at a glance:

  • Only 56.5% outside-diagnosis confirmation rate — Guo et al. 2017 two-center Chinese expert review confirmed just 52 of 92 submitted mesothelioma specimens, dropping to 35.3% for pleural cases alone[1]
  • 1 in 4 pleural patients initially misdiagnosed — most frequently as lung cancer or adenocarcinoma because of morphological overlap with epithelioid mesothelioma[3][5]
  • Peritoneal mesothelioma most often mistaken for ovarian cancer — case series report patients undergoing full ovarian debulking surgery before correct diagnosis is established[11][12][8]
  • Median 6.5 months to specialist referral — Gregório et al. 2022 documented an interquartile range of 2.0–11.4 months from symptom onset to first specialist visit in a 66-patient MPM cohort[6]
  • French National Surveillance: 67% confirmation rate — Goldberg et al. (2006) expert panel ruled out mesothelioma in 13% of submitted cases and left 20% uncertain[1]
  • Chinese reference centers: 56.5% confirmation — Guo et al. 2017 confirmed only 12 of 34 pleural mesothelioma cases (35.3%) and 38 of 56 peritoneal (67.9%) on expert review[1]
  • Brazilian 482-case hospital registry: 12% diagnostic improvement after board review — community pathology produced incomplete or mistaken diagnoses in a meaningful share of cases[13]
  • 57.1% Cope needle biopsy false-negative rate — the Gregório cohort required re-biopsy in over 60% of patients referred without a definitive diagnosis[6]
  • Japan: 10–15% inadequate diagnosis — the Japanese committee for patient relief judged ~30% of applicants as not having mesothelioma or requiring additional evidence[14]
  • Comorbidity adds 27.6 days per condition — a UK cohort study of >10,000 patients found diagnostic intervals lengthened substantially when "alternative explanation" conditions (COPD, heart disease) coexisted[15]

Key Facts

Measure Finding (Source)
Initial pleural misdiagnosis rate ~1 in 4 patients receive a wrong initial diagnosis — most commonly lung cancer / adenocarcinoma[3][5]
Specialist referral delay (pleural) Median 6.5 months (IQR 2.0–11.4) from symptom onset — Gregório et al. 2022, n=66[6]
Peritoneal mesothelioma delay Typically ~4 months from symptom onset due to nonspecific abdominal symptoms that often delay specialist referral[2]
French National Surveillance confirmation 67% confirmed, 13% ruled out, 20% uncertain — Goldberg et al. 2006 expert panel[1]
Chinese reference centers (overall) 52 of 92 cases (56.5%) confirmed — Guo et al. 2017[1]
Chinese centers (pleural only) 12 of 34 cases (35.3%) confirmed — pleural mesothelioma hardest to verify[1]
Brazilian São Paulo registry 482 cases, 130 required histological revision; diagnostic accuracy improved 12% after expert board review[13]
Japanese committee data ~10–15% receive inadequate diagnosis; ~30% of applicants judged not to have mesothelioma or deferred[14]
Cope needle biopsy false-negative rate 57.1% — a majority of referred patients required re-biopsy[6]
Comorbidity diagnostic interval +27.6 days per condition; +72 days with ≥2 "alternative explanation" conditions — UK cohort, >10,000 patients[15][16]
5-year survival (localized vs. distant) ~20% vs. ~8% — delay collapses the curative-intent surgical window[7]

Why Is Mesothelioma So Frequently Misdiagnosed?

Mesothelioma is a rare cancer — roughly 3,000 new U.S. cases per year — with a latency period of 20 to 50 years from asbestos exposure to disease onset.[17][18] That combination of rarity and long latency means most primary care physicians and even many oncologists will see only a handful of mesothelioma cases in an entire career, and the patients who do present are typically older, with symptoms that overlap with far more common conditions: lung cancer, chronic obstructive pulmonary disease (COPD), pneumonia, bronchitis, heart disease, or benign pleural plaques.[5][8]

At the pathology level, epithelioid mesothelioma — the most common histologic subtype — shares morphological features with adenocarcinoma. Distinguishing the two requires a multi-stain immunohistochemistry panel: calretinin (80–100% sensitive for epithelioid mesothelioma but negative in lung adenocarcinoma), WT-1 (70–100% sensitive for mesothelioma), D2-40, and claudin-4 (92–100% sensitivity and 94–100% specificity for carcinoma versus mesothelioma). Loss of BAP1 nuclear staining and MTAP deletion by FISH are additional discriminators for malignant from reactive mesothelial proliferations.[9] Pathologists at non-specialist centers who lack access to the full panel — or who interpret stains without the volume of case experience needed for confidence — are the dominant source of diagnostic error. Guo and colleagues specifically attributed diagnostic inaccuracy to "the use of an incomplete set of immunostains and/or the incorrect interpretation of the stains, as well as an overall tendency to make a definitive diagnosis even when the evidence was inadequate."[1]

What Are the Most Common Wrong Diagnoses?

The most frequently reported initial misdiagnoses fall into distinct patterns by mesothelioma subtype.

Pleural mesothelioma is most commonly confused with:

  • Lung cancer or adenocarcinoma — the leading pathology-level error; morphological similarity plus overlapping radiographic presentation make this the single most dangerous diagnostic trap[19][10]
  • Pneumonia or bronchitis — common at the symptom level; cough, dyspnea, and chest pain mimic lower respiratory infection[5]
  • COPD — chronic respiratory symptoms in older patients often get attributed to smoking history rather than a new malignancy
  • Pleural plaques — benign asbestos-related lesions that can coexist with mesothelioma and distract from the true cancer
  • Heart disease — large pleural effusions cause breathlessness that is sometimes attributed to congestive heart failure before imaging points to the pleura

Peritoneal mesothelioma is most commonly confused with:

  • Ovarian cancer — the most prominent peritoneal trap, particularly in women. Case series have documented patients who underwent full ovarian debulking surgery under the presumption of ovarian malignancy before correct mesothelioma diagnosis was established. One published case series reported 8 peritoneal mesothelioma cases that initially presented as peritoneal carcinoma or ovarian cancer[11][12]
  • Irritable bowel syndrome (IBS) and other gastrointestinal conditions — nonspecific bloating, pain, and constipation delay referral for imaging[8]
  • Peritoneal carcinomatosis from an unknown primary — pathology reports may attribute disease to "metastatic adenocarcinoma, primary unknown" until immunohistochemistry is performed[1]
  • Pancreatic or colon cancer — overlapping abdominal symptoms and imaging findings

How Often Are Mesothelioma Diagnoses Overturned on Expert Pathology Review?

Expert review of mesothelioma pathology is one of the most consistently studied quality checks in the literature, and the findings are sobering. Across multiple independent cohorts, expert panels routinely overturn or question a substantial share of outside diagnoses.[1][9]

  • French National Mesothelioma Surveillance Program (Goldberg et al. 2006) — confirmed the diagnosis in 67% of submitted cases, ruled it out in 13%, and left 20% uncertain on expert panel review.[1]
  • Guo et al. 2017 (China) — confirmed mesothelioma in only 52 of 92 (56.5%) specimens submitted from two reference centers. Pleural confirmation rate was 12 of 34 (35.3%); peritoneal was 38 of 56 (67.9%). The most common misdiagnoses were metastatic carcinomas (lung, ovary) and poorly differentiated carcinomas of unknown primary.[1]
  • Brazil São Paulo Pathological Survey (Gregório et al. 2024) — reviewed 482 cases from 25 hospitals. 130 required further histological revision, and the diagnostic rate improved by 12% after expert board analysis. Two previously diagnosed mesotheliomas were discarded on review.[13]
  • Japan — approximately 10–15% of mesothelioma patients receive an inadequate diagnosis. In the Japanese committee for patient relief, ~30% of applicants were judged as not having mesothelioma or the decision was deferred pending additional evidence.[14]
  • Monte Carlo Analysis (Bentham Open Epidemiology) — cancer registry studies that confirmed mesothelioma via expert review found 17–25% of prior registry-recorded cases were misclassified.[3]

These are not failures of individual pathologists so much as failures of infrastructure. Expert panel review works — every study that applied one improved diagnostic accuracy substantially — and the policy implication is that rare-cancer pathology should be centralized at high-volume centers wherever possible.[9][4]

How Many Doctors Do Patients See Before a Correct Diagnosis?

Published data on exactly how many physicians a mesothelioma patient sees before correct diagnosis is limited, but the available evidence paints a consistent picture of extensive workup before confirmation.

The Gregório 2022 cohort found that patients underwent a median of 2 procedures (range 0–5) before specialist referral, and over 60% were referred to a specialist without a definitive biopsy or diagnosis. After specialist referral, many required re-biopsy due to false-negative results — the Cope needle biopsy alone had a 57.1% false-negative rate in this cohort.[6] A 2022 case report documented a 65-year-old patient whose mesothelioma required three separate biopsy attempts before pathologists could identify the malignancy, ultimately requiring robot-assisted thoracoscopic surgery for adequate tissue sampling.[20]

The practical takeaway for patients and families is that a persistent chest or abdominal symptom complex in a patient with any asbestos exposure history — even exposure that occurred decades earlier — warrants insistence on a second opinion at a specialist mesothelioma center rather than acceptance of a community hospital's first diagnostic interpretation.[4][10][5]

How Does Delayed Diagnosis Affect Survival?

Delayed diagnosis compresses the window for curative-intent treatment and shifts patients from surgical candidacy toward palliative care. The 5-year survival rate for localized pleural mesothelioma is approximately 20%, compared to roughly 8% for distant/advanced disease — the gap that early diagnosis is meant to close.[7][21] The Gregório cohort concluded that the overall survival of less than 1 year (mean 11.9 months) in their patients was "likely to have been due to the aforementioned delays" in diagnosis. Less than 20% of patients in that study could undergo surgery, owing to advanced staging and poor performance status at the time of referral.[6]

The Gregório et al. 2022 cohort concluded explicitly that the overall mean survival of 11.9 months in their 66-patient MPM series was "likely to have been due to the aforementioned delays" in specialist referral and histopathological confirmation — direct clinical evidence that diagnostic delay translates into measurably worse survival in real-world mesothelioma cohorts.[6][21]

A paradoxical-sounding 2024 SEER analysis of 4,879 MPM patients by Kulshrestha and colleagues at Mount Sinai found that patients with longer time-to-treatment initiation (>39 days from diagnosis) had better median survival (13 vs. 10 months; adjusted HR 0.79, 95% CI: 0.74–0.84). The authors attributed this to the fact that longer time-to-treatment typically reflects referral to high-volume specialized centers for comprehensive staging and multidisciplinary planning, rather than that delay itself is beneficial.[22] The finding reinforces that where and how patients are treated matters at least as much as how fast — a blunt time-to-treatment metric would mislead if taken in isolation.

Why Do Specialist Centers Outperform Community Hospitals?

The literature strongly supports the conclusion that diagnostic accuracy for mesothelioma differs substantially between general community hospitals and specialized mesothelioma centers. The drivers are concrete:

  1. Full immunohistochemistry panels. Specialist centers routinely run calretinin, WT-1, D2-40, claudin-4, BAP1, and MTAP. Community labs frequently lack one or more stains, or interpret them without the comparative case volume needed for reliable diagnosis.[9]
  2. Thoracic-pathology expertise. The Lucà et al. 2025 review noted that "the rarity of this neoplasm, combined with the shortage of pathologists and particularly the lack of professionals specialized in thoracic pathology in many centers" was a primary contributor to diagnostic difficulty.[9]
  3. Multidisciplinary team review. Specialist mesothelioma centers convene multidisciplinary tumor boards (thoracic surgery, medical oncology, radiation oncology, pathology, radiology, pulmonology) for every case, and this combined review materially improves treatment quality and evidence-based decision-making. Community hospitals without dedicated mesothelioma MDTs rarely replicate this coordination.[4]
  4. Referral distance correlates with outcome. Travel distance to specialist centers has been shown to be positively associated with survival in operable MPM — patients who travel farther to reach high-volume centers receive higher-quality care despite the logistical burden.[22]

The combined summary from cross-country pathology review data:

Setting Confirmation Rate Source
French National Surveillance (expert review) 67% confirmed Goldberg et al. 2006[1]
Chinese reference centers (overall) 56.5% confirmed Guo et al. 2017[1]
Chinese centers (pleural only) 35.3% confirmed Guo et al. 2017[1]
Brazilian hospital registry (post expert review) +12% improvement Gregório et al. 2024[13]

What Should a Patient Do if They Suspect a Mesothelioma Misdiagnosis?

  1. Get a second opinion at a high-volume mesothelioma center. Pathology slides and imaging can be mailed or transferred electronically; patients do not need to travel for the initial review. Specialist centers typically offer rapid slide review programs that can confirm or revise a diagnosis within days.[4][5]
  2. Request a full immunohistochemistry panel. Any mesothelioma diagnosis made without at least calretinin, WT-1, and claudin-4 is incomplete. If the pathology report lists fewer stains, request additional testing before treatment planning.[9]
  3. Document the exposure history. A detailed occupational, military, and environmental asbestos exposure history — including spouses and children of workers with secondary take-home exposure — strengthens both clinical suspicion and any subsequent legal claim. Patients aware of prior asbestos exposure had significantly shorter referral times in the Gregório cohort (median 120 vs. 214 days; p=0.04).[6][18]
  4. Preserve tissue from prior biopsies. If an initial biopsy was inconclusive, the tissue block may still be re-stained by a specialist pathologist rather than requiring a new procedure.[5]
  5. Consider a multidisciplinary team review. At large cancer centers, MDT review typically includes a thoracic surgeon, medical oncologist, radiation oncologist, pathologist, radiologist, and pulmonologist — the combination that produces the highest-quality treatment plan.[4]
  6. Consult an experienced mesothelioma attorney. Diagnostic delay caused by pathology error or failure to consider asbestos exposure may be relevant to both medical treatment planning and any subsequent legal claim against responsible asbestos manufacturers. Time limits (statutes of limitation) vary by state and begin to run at diagnosis, so early legal consultation is important regardless of the treatment path.[4][10]

Frequently Asked Questions

How often is mesothelioma misdiagnosed?

Published expert-review studies indicate that a large share of outside mesothelioma diagnoses are revised when examined by specialist thoracic pathologists. The French National Mesothelioma Surveillance Program confirmed just 67% of submitted cases; the Guo et al. 2017 two-center Chinese study confirmed only 56.5% overall and 35.3% for pleural cases; and the Brazilian São Paulo registry required histological revision of 130 of 482 cases. Registry-level Monte Carlo analyses put the misclassification rate at 17–25%. For pleural mesothelioma specifically, about 1 in 4 patients receives an initial wrong diagnosis, most commonly lung cancer or adenocarcinoma.[1][13][3]

What is mesothelioma most commonly misdiagnosed as?

Pleural mesothelioma is most commonly misdiagnosed as lung cancer or adenocarcinoma because of morphological similarity at the pathology level, and at the symptom level as pneumonia, bronchitis, COPD, or heart disease. Peritoneal mesothelioma is most commonly misdiagnosed as ovarian cancer in women — case series describe patients undergoing full ovarian debulking surgery before correct diagnosis — and as irritable bowel syndrome, other abdominal cancers, or peritoneal carcinoma from an unknown primary.[11][12][5][8]

Why is mesothelioma so hard to diagnose correctly?

Three factors combine to make mesothelioma uniquely difficult. First, it is rare — about 3,000 U.S. cases per year — so most physicians have limited direct case experience. Second, it has a 20- to 50-year latency period from asbestos exposure, so the exposure history is often distant and incompletely remembered. Third, at the pathology level, epithelioid mesothelioma closely resembles adenocarcinoma, and distinguishing the two requires a multi-stain immunohistochemistry panel (calretinin, WT-1, D2-40, claudin-4, BAP1, MTAP) that not every community hospital lab can run or interpret reliably.[17][9][18]

Should I get a second opinion if I'm diagnosed with mesothelioma?

Yes — and at a high-volume specialist mesothelioma center, not just a general oncologist. Expert pathology review consistently overturns a meaningful share of outside diagnoses, and specialist centers run the full immunohistochemistry panels needed to distinguish mesothelioma from its imitators. Slides and imaging can usually be mailed or transferred electronically for review, so patients do not need to travel for the initial consultation. A second opinion may also reveal access to clinical trials, surgical options, or multidisciplinary programs not available at community hospitals.[9][5][10]

Does a misdiagnosis affect a mesothelioma lawsuit?

A pathology error or missed asbestos exposure history does not by itself create a separate legal claim in most states, but it can be relevant to the timing of a mesothelioma lawsuit against asbestos manufacturers and trust funds. Statutes of limitation typically begin to run at the date of a correct diagnosis, and diagnostic delay may affect what treatment options were realistically available. An experienced mesothelioma attorney can evaluate how a delayed or incorrect diagnosis interacts with the specific facts of a patient's exposure history and compensation options.[4][5]

How long does diagnostic delay typically shorten a mesothelioma patient's life?

The 5-year survival gap between localized (~20%) and distant/advanced (~8%) pleural mesothelioma captures the core stakes: diagnostic delay that moves a patient from stage I–II to stage III–IV can effectively halve the 5-year survival rate and eliminate the possibility of curative-intent surgery. In the Gregório et al. 2022 cohort, the combined delay between first symptom, specialist visit, histopathological confirmation, and treatment initiation was associated with a mean overall survival of just 11.9 months, which the authors attributed directly to diagnostic delay.[7][6]

Quick Statistics

  • 1 in 4: pleural mesothelioma patients initially misdiagnosed, most commonly as lung cancer[3]
  • 17–25%: cancer registry misclassification rate found on expert review (Monte Carlo analysis)[3]
  • 6.5 months: median time from symptom onset to first specialist visit (Gregório 2022)[6]
  • 67%: confirmation rate on expert review by French National Mesothelioma Surveillance Program[1]
  • 56.5%: confirmation rate at two Chinese reference centers (Guo 2017)[1]
  • 35.3%: confirmation rate for pleural cases in the Guo 2017 study — the lowest in the published literature[1]
  • 130 of 482: Brazilian hospital registry cases that required histological revision on expert panel review[13]
  • 57.1%: Cope needle biopsy false-negative rate in the Gregório cohort[6]
  • 20% vs. 8%: 5-year survival for localized vs. distant pleural mesothelioma[7]
  • 20–50 years: latency period from asbestos exposure to mesothelioma diagnosis[17]

Get Help

If you or a loved one has received a mesothelioma diagnosis — or suspects a misdiagnosis based on an unexplained symptom complex and a history of asbestos exposure — legal and medical help is available. An experienced mesothelioma attorney can help coordinate second-opinion pathology review, evaluate compensation options, and protect the filing deadlines that begin at diagnosis.

  • Danziger & De Llano — National mesothelioma law firm offering free, confidential case evaluations and connection to specialist treatment centers. Call (866) 222-9990.
  • Mesothelioma Lawyers Near Me — Find experienced mesothelioma attorneys near you with free case review resources.


⚠ Statute of Limitations Warning: Filing deadlines vary by state from 1-6 years from diagnosis. Texas allows 2 years from diagnosis or discovery. Contact an attorney immediately to preserve your rights.

References

  1. ↑ 1.00 1.01 1.02 1.03 1.04 1.05 1.06 1.07 1.08 1.09 1.10 1.11 1.12 1.13 1.14 1.15 1.16 1.17 1.18 1.19 Improving the Accuracy of Mesothelioma Diagnosis in China, PMC / National Library of Medicine (Guo et al. 2017). 52/92 (56.5%) overall confirmation, 12/34 (35.3%) pleural, 38/56 (67.9%) peritoneal.
  2. ↑ 2.0 2.1 Unraveling Peritoneal Mesothelioma: A Case-Based Discussion on Diagnosis and Delay, PMC / National Library of Medicine. Documents typical ~4-month delay from symptom onset in peritoneal mesothelioma.
  3. ↑ 3.0 3.1 3.2 3.3 3.4 3.5 3.6 Monte Carlo Analysis of Impact of Underascertainment of Mesothelioma Cases, The Open Epidemiology Journal. Cancer registry studies that confirmed diagnoses via expert review found 17–25% were previously misclassified.
  4. ↑ 4.0 4.1 4.2 4.3 4.4 4.5 4.6 4.7 4.8 Mesothelioma Diagnosis, Danziger & De Llano.
  5. ↑ 5.00 5.01 5.02 5.03 5.04 5.05 5.06 5.07 5.08 5.09 5.10 5.11 Mesothelioma Diagnosis, Mesothelioma Lawyer Center.
  6. ↑ 6.00 6.01 6.02 6.03 6.04 6.05 6.06 6.07 6.08 6.09 6.10 6.11 Mesothelioma in a developing country: a retrospective analysis of the diagnostic process, PMC / National Library of Medicine (Gregório et al. 2022). Median 6.5-month referral delay, 57.1% Cope needle false-negative rate, n=66 MPM patients.
  7. ↑ 7.0 7.1 7.2 7.3 7.4 Malignant Mesothelioma Treatment — National Cancer Institute, National Cancer Institute (NIH). Stage-stratified survival data.
  8. ↑ 8.0 8.1 8.2 8.3 8.4 Mesothelioma Diagnosis, Mesothelioma.net.
  9. ↑ 9.0 9.1 9.2 9.3 9.4 9.5 9.6 9.7 9.8 Diagnostic Challenges in the Pathological Approach to Pleural Mesothelioma, PMC / National Library of Medicine (Lucà et al. 2025). Review of immunohistochemistry panel requirements and thoracic pathology shortages.
  10. ↑ 10.0 10.1 10.2 10.3 10.4 Mesothelioma Diagnosis, MesotheliomaAttorney.com.
  11. ↑ 11.0 11.1 11.2 A case of mesothelioma masquerading pre-operatively as ovarian cancer, PMC / National Library of Medicine. Case report of initial ovarian misdiagnosis.
  12. ↑ 12.0 12.1 12.2 Malignant peritoneal mesothelioma presented as peritoneal adenocarcinoma or primary ovarian cancer: case series, PMC / National Library of Medicine. 8-case series of peritoneal mesothelioma initially diagnosed as ovarian or peritoneal carcinoma.
  13. ↑ 13.0 13.1 13.2 13.3 13.4 13.5 Identifying malignant mesothelioma by a pathological survey using the São Paulo state hospital cancer registry, Brazil, PMC / National Library of Medicine (Gregório et al. 2024). 482 cases, 130 requiring histological revision, 12% diagnostic improvement post-review.
  14. ↑ 14.0 14.1 14.2 Pathology of mesothelioma, PMC / National Library of Medicine. Japanese committee data — 10–15% inadequate diagnosis, ~30% of applicants ruled out or deferred.
  15. ↑ 15.0 15.1 The effect of comorbidities on diagnostic interval for lung cancer and mesothelioma: A cohort study, PMC / National Library of Medicine. 27.6 day delay per alternative-explanation condition.
  16. ↑ The effect of comorbidities on diagnostic interval for lung cancer and mesothelioma: A cohort study using linked data from the Clinical Practice Research Datalink and the Cancer Registry, International Journal of Population Data Science. >10,000 patient cohort.
  17. ↑ 17.0 17.1 17.2 Toxicological Profile for Asbestos, Agency for Toxic Substances and Disease Registry (ATSDR/CDC). Latency period data.
  18. ↑ 18.0 18.1 18.2 Asbestos Exposure and Mesothelioma, Danziger & De Llano.
  19. ↑ Intrapulmonary Biphasic Mesothelioma Misdiagnosed as Poorly Differentiated Adenocarcinoma, PMC / National Library of Medicine. Case of intrapulmonary mesothelioma initially misdiagnosed as adenocarcinoma until calretinin, D2-40, WT-1 immunohistochemistry revision.
  20. ↑ Mesothelioma: A Case in a Diagnostic Timeline and the Efficiency of Robot-Assisted Surgery, PMC / National Library of Medicine. Three biopsy attempts before definitive diagnosis.
  21. ↑ 21.0 21.1 Diagnosis, Screening, and Early Detection of Mesothelioma, Massive Bio. Overview of early detection impact on prognosis.
  22. ↑ 22.0 22.1 Paradoxical Improvement in Malignant Pleural Mesothelioma Outcomes Following Delayed Treatment Initiation, PMC / National Library of Medicine (Kulshrestha et al., Mount Sinai). SEER analysis of 4,879 MPM patients; adjusted HR 0.79 (95% CI 0.74–0.84) favoring delayed-TTI subset reflecting specialist referral.
Retrieved from "https://wikimesothelioma.com/index.php?title=Mesothelioma_Misdiagnosis&oldid=2183"